497 related articles for article (PubMed ID: 20201845)
1. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
Heidbreder CA; Newman AH
Ann N Y Acad Sci; 2010 Feb; 1187():4-34. PubMed ID: 20201845
[TBL] [Abstract][Full Text] [Related]
2. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
Heidbreder C
CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
[TBL] [Abstract][Full Text] [Related]
3. Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.
Heidbreder C
Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):167-76. PubMed ID: 23104235
[TBL] [Abstract][Full Text] [Related]
4. Selective dopamine D3 receptor antagonists: a review 2001-2005.
Micheli F; Heidbreder C
Recent Pat CNS Drug Discov; 2006 Nov; 1(3):271-88. PubMed ID: 18221209
[TBL] [Abstract][Full Text] [Related]
5. Current Perspectives on Selective Dopamine D
Newman AH; Xi ZX; Heidbreder C
Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
Xi ZX; Gardner EL
CNS Drug Rev; 2007; 13(2):240-59. PubMed ID: 17627675
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 receptor antagonists: a patent review (2007 - 2012).
Micheli F; Heidbreder C
Expert Opin Ther Pat; 2013 Mar; 23(3):363-81. PubMed ID: 23282131
[TBL] [Abstract][Full Text] [Related]
8. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.
Newman AH; Blaylock BL; Nader MA; Bergman J; Sibley DR; Skolnick P
Biochem Pharmacol; 2012 Oct; 84(7):882-90. PubMed ID: 22781742
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.
Mason CW; Hassan HE; Kim KP; Cao J; Eddington ND; Newman AH; Voulalas PJ
J Pharmacol Exp Ther; 2010 Jun; 333(3):854-64. PubMed ID: 20228156
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D3 receptor antagonists as therapeutic agents.
Joyce JN; Millan MJ
Drug Discov Today; 2005 Jul; 10(13):917-25. PubMed ID: 15993811
[TBL] [Abstract][Full Text] [Related]
11. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.
Heidbreder CA; Gardner EL; Xi ZX; Thanos PK; Mugnaini M; Hagan JJ; Ashby CR
Brain Res Brain Res Rev; 2005 Jul; 49(1):77-105. PubMed ID: 15960988
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
[TBL] [Abstract][Full Text] [Related]
13. Blockade of dopamine D3 receptors in the nucleus accumbens and central amygdala inhibits incubation of cocaine craving in rats.
Xi ZX; Li X; Li J; Peng XQ; Song R; Gaál J; Gardner EL
Addict Biol; 2013 Jul; 18(4):665-77. PubMed ID: 22913325
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.
Le Foll B; Collo G; Rabiner EA; Boileau I; Merlo Pich E; Sokoloff P
Prog Brain Res; 2014; 211():255-75. PubMed ID: 24968784
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.
Vorel SR; Ashby CR; Paul M; Liu X; Hayes R; Hagan JJ; Middlemiss DN; Stemp G; Gardner EL
J Neurosci; 2002 Nov; 22(21):9595-603. PubMed ID: 12417684
[TBL] [Abstract][Full Text] [Related]
16. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.
Song R; Yang RF; Wu N; Su RB; Li J; Peng XQ; Li X; Gaál J; Xi ZX; Gardner EL
Addict Biol; 2012 Mar; 17(2):259-73. PubMed ID: 21507153
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.
Micheli F
ChemMedChem; 2011 Jul; 6(7):1152-62. PubMed ID: 21425240
[TBL] [Abstract][Full Text] [Related]
18. Computational modelling reveals contrasting effects on reinforcement learning and cognitive flexibility in stimulant use disorder and obsessive-compulsive disorder: remediating effects of dopaminergic D2/3 receptor agents.
Kanen JW; Ersche KD; Fineberg NA; Robbins TW; Cardinal RN
Psychopharmacology (Berl); 2019 Aug; 236(8):2337-2358. PubMed ID: 31324936
[TBL] [Abstract][Full Text] [Related]
19. The dopamine D3 receptor, a quarter century later.
Sokoloff P; Le Foll B
Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596
[TBL] [Abstract][Full Text] [Related]
20. Use of animal models to develop antiaddiction medications.
Gardner EL
Curr Psychiatry Rep; 2008 Oct; 10(5):377-84. PubMed ID: 18803910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
